Acadia Pharmaceuticals Files 2024 10-K
Ticker: ACAD · Form: 10-K · Filed: 2025-02-27T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Acadia dropped its 2024 10-K. Full financials and biz details inside.
AI Summary
Acadia Pharmaceuticals Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in San Diego, CA, operates in the pharmaceutical preparations sector. Key financial data and operational details for the fiscal year 2024 are presented in this comprehensive annual report.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Acadia's financial performance, strategic initiatives, and risk factors for the fiscal year 2024, crucial for understanding the company's current standing and future outlook.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Acadia faces inherent risks related to drug development, regulatory approvals, market competition, and patent expirations.
Key Numbers
- 1231 — Fiscal Year End (The report covers the fiscal year ending on this date.)
- 20250227 — Filing Date (The date the 10-K was officially submitted to the SEC.)
Key Players & Entities
- ACADIA PHARMACEUTICALS INC (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-02-27 (date) — Filing Date
- SAN DIEGO, CA (location) — Business Address
FAQ
What is Acadia Pharmaceuticals Inc.'s primary business sector?
Acadia Pharmaceuticals Inc. operates in the Pharmaceutical Preparations sector, with the Standard Industrial Classification code [2834].
When did Acadia Pharmaceuticals Inc. file its 2024 10-K report?
The 10-K report for the fiscal year ending December 31, 2024, was filed on February 27, 2025.
Where is Acadia Pharmaceuticals Inc. headquartered?
Acadia Pharmaceuticals Inc.'s business and mailing address is 12830 El Camino Real, Suite 400, San Diego, CA 92130.
What is the SEC file number for Acadia Pharmaceuticals Inc.'s 10-K filing?
The SEC file number for this 10-K filing is 000-50768.
What is the Central Index Key (CIK) for Acadia Pharmaceuticals Inc.?
The Central Index Key (CIK) for Acadia Pharmaceuticals Inc. is 0001070494.
From the Filing
0000950170-25-029253.txt : 20250227 0000950170-25-029253.hdr.sgml : 20250227 20250227172609 ACCESSION NUMBER: 0000950170-25-029253 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250227 DATE AS OF CHANGE: 20250227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 25680967 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 10-K 1 acad-20241231.htm 10-K 10-K 0001070494 FY false http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent 0001070494 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001070494 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember acad:UpfrontAndMilestonePaymentsMember 2024-01-01 2024-12-31 0001070494 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-12-31 0001070494 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001070494 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001070494 us-gaap:ConstructionMember 2024-12-31 0001070494 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001070494 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001070494 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember acad:DaybueMember 2023-01-01 2023-12-31 0001070494 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001070494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001070494 acad:CorporateOfficeSpaceLeaseAgreementMember 2018-12-31 0001070494 acad:CorporateOfficeSpaceLeaseAgreementMember stpr:CA 2020-03-31 0001070494 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001070494 acad:LicenseAgreementsMember acad:SanionaMember srt:MaximumMember 2024-11-30 0001070494 us-gaap:PerformanceSharesMember srt:MinimumMember 2024-01-01 2024-12-31 0001070494 acad:AllowanceForDistributionFeesDiscountsAndChargebacksMember 2024-01-01 2024-12-31 0001070494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001070494 acad:DaybueMember 2022-01-01 2022-12-31 0001070494 acad:RevenueConcentrationRiskMember acad:CustomerDMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0001070494 acad:StokeTherapeuticsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-31 0001070494 acad:TwoThousandTenEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember 2019-06-01 2019-06-30 0001070494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001070494 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember acad:InternalCostsMember 2023-01-01 2023-12-31 0001070494 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2022-01-01 2022-12-31 0001070494 us-gaap:DomesticCountryMember 2024-12-31 0001070494 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001070494 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001070494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001070494 acad:RevenueConcentrationRiskMember acad:CustomerDMember us-gaap:SalesRevenueNetMember 2024-01-01 2024-12-31 0001070494 acad:LicenseAgreementsMember acad:NeurenPharmaceuticalsLimitedMember srt:MaximumMember srt:NorthAmericaMember 2023-07-31 0001070494 us-gaap:AdditionalPaid